The measurable indicators that guide drug discovery, patient selection, and treatment monitoring - and how NAMs are revolutionizing biomarker research
A biomarker is any measurable characteristic that indicates a biological state, disease process, or response to treatment. Biomarkers can be molecular (genes, proteins, metabolites), cellular, physiological (blood pressure, heart rate), or imaging-based. They serve as the bridge between laboratory research and clinical medicine.
Used to detect or confirm the presence of a disease or condition. Essential for patient identification and enrollment in clinical trials.
Indicate the likely course of disease regardless of treatment. Help predict patient outcomes and disease severity.
Identify patients likely to benefit from a specific therapy. Essential for targeted drug development and companion diagnostics.
Show whether a drug is having its intended biological effect. Used to confirm mechanism of action and optimize dosing.
Detect adverse effects before clinical symptoms appear. Critical for monitoring toxicity and stopping treatment early if needed.
Substitute for clinical outcomes to accelerate drug approval. Must be validated as reliable predictors of patient benefit.
Organoids and organ-chips analyzed for gene expression, proteins, and metabolites
Machine learning identifies correlations between molecular signatures and drug response
Candidate biomarkers tested across diverse patient-derived samples
FDA review and approval for use in drug development or clinical care
Organoids from individual patients reveal biomarkers that predict drug response. By testing drugs on patient tissue, researchers identify molecular signatures that distinguish responders from non-responders.
Integrated biosensors in organ-chips continuously monitor secreted biomarkers, oxygen consumption, and cellular stress responses in real-time, capturing dynamic changes that predict toxicity.
Machine learning algorithms analyze massive datasets from NAMs experiments, clinical records, and genomic databases to discover novel biomarker candidates and validate existing ones.
Virtual patient models integrate biomarker data with physiological simulations to predict individual drug responses and identify optimal biomarker thresholds for treatment decisions.
| Biomarker | Disease | Type | Clinical Use |
|---|---|---|---|
| HER2 | Breast Cancer | Predictive | Trastuzumab (Herceptin) eligibility |
| EGFR mutations | Lung Cancer | Predictive | TKI therapy selection (erlotinib, gefitinib) |
| KRAS G12C | Lung/Colorectal Cancer | Predictive | Sotorasib eligibility |
| PD-L1 | Multiple Cancers | Predictive | Checkpoint inhibitor response prediction |
| BRCA1/2 | Breast/Ovarian Cancer | Diagnostic/Predictive | PARP inhibitor eligibility |
| MSI-H/dMMR | Multiple Cancers | Predictive | Pembrolizumab (tumor-agnostic approval) |
| ALK rearrangement | Lung Cancer | Predictive | Crizotinib, alectinib eligibility |
| BCR-ABL | CML | Diagnostic/Monitoring | Imatinib response and resistance monitoring |
Learn how biomarkers are transforming drug development and personalized medicine
Precision Medicine AI Drug Discovery Clinical Trials© 2025 Patient Analog. All rights reserved.
Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.
Free to share for educational purposes with attribution.